# A Randomized, Single-Dose, Comparative, Positive and Placebo Controlled, Four-Way, Four Period, Cross-Over Study to Evaluate the Effect of DIC075V on QTc Intervals in Healthy Subjects

> **NCT01812538** · PHASE1 · COMPLETED · sponsor: **Hospira, now a wholly owned subsidiary of Pfizer** · enrollment: 70 (actual)

## Conditions studied

- Ventricular Repolarization

## Interventions

- **DRUG:** DIC075V

## Key facts

- **NCT ID:** NCT01812538
- **Lead sponsor:** Hospira, now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2009-07
- **Final completion:** 2009-07
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2015-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01812538

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01812538, "A Randomized, Single-Dose, Comparative, Positive and Placebo Controlled, Four-Way, Four Period, Cross-Over Study to Evaluate the Effect of DIC075V on QTc Intervals in Healthy Subjects". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT01812538. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*